Sellas Life Sciences Group (SLS)
NASDAQ:SLS
Want to see SLS full AI Analyst Report?
Top Page
SELLAS Life Sciences Group
(NASDAQ:SLS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$9.00
▲(118.98% Upside)
Action:Reiterated
Date:06/02/26
The score is held back primarily by very weak operating fundamentals—no meaningful revenue, continuing losses, and negative free cash flow—despite a low-debt, better-capitalized balance sheet. Technicals are a notable positive with strong uptrends, but overbought readings add risk. Liquidity-boosting warrant exercises help near-term runway, though dilution remains a meaningful downside.
Positive Factors
Balance sheet strength
Extremely low debt and materially improved equity provide financial flexibility to fund clinical programs and absorb near-term losses. This reduces bankruptcy risk and makes the company a more credible partner for collaborations or non-dilutive funding over the next several months.
Negative Factors
No meaningful revenue
The absence of a revenue base means the business cannot internally fund operations or scale without external capital. Persistent losses compress returns and force reliance on financing events, making long-term sustainability contingent on trial success or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Extremely low debt and materially improved equity provide financial flexibility to fund clinical programs and absorb near-term losses. This reduces bankruptcy risk and makes the company a more credible partner for collaborations or non-dilutive funding over the next several months.
Read all positive factors
SELLAS Life Sciences Group (SLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.68B
Dividend YieldN/A
Average Volume (3M)9.21M
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth41.60%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding186,032,580
10 Day Avg. Volume12,338,951
30 Day Avg. Volume9,205,195
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-51.22
Forecast
1Y Price Target
$10.00Price Target Upside143.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$36.13M
SELLAS Life Sciences Group Business Overview & Revenue Model
Company Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer ...
How the Company Makes Money
null...
SELLAS Life Sciences Group Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 7.60M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 900.00K | 7.40M |
| EBITDA | -23.82M | -28.27M | 632.00K | 529.00K | -31.49M | -18.32M |
| Net Income | -29.46M | -26.86M | -30.88M | -37.34M | -41.30M | -20.70M |
Balance Sheet | ||||||
| Total Assets | 114.18M | 78.34M | 19.43M | 6.22M | 20.94M | 26.43M |
| Cash, Cash Equivalents and Short-Term Investments | 107.20M | 71.89M | 13.89M | 2.53M | 17.13M | 21.45M |
| Total Debt | 871.00K | 1.00M | 1.00M | 906.00K | 945.00K | 808.00K |
| Total Liabilities | 6.76M | 7.47M | 9.97M | 14.20M | 16.09M | 6.08M |
| Stockholders Equity | 107.41M | 70.87M | 9.46M | -7.98M | 4.85M | 20.35M |
Cash Flow | ||||||
| Free Cash Flow | -28.16M | -28.39M | -35.40M | -36.91M | -28.31M | -26.02M |
| Operating Cash Flow | -28.16M | -28.39M | -35.40M | -31.41M | -23.81M | -26.02M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -5.50M | -4.50M | 0.00 |
| Financing Cash Flow | 106.86M | 86.30M | 46.76M | 22.32M | 24.08M | 12.07M |
SELLAS Life Sciences Group Technical Analysis
Positive
4.11
Price Trends
5.92
Positive
5.23
Positive
3.64
Positive
Market Momentum
0.86
Positive
57.21
Neutral
55.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLS, the sentiment is Positive. The current price of 4.11 is below the 20-day moving average (MA) of 7.69, below the 50-day MA of 5.92, and above the 200-day MA of 3.64, indicating a bullish trend. The MACD of 0.86 indicates Positive momentum. The RSI at 57.21 is Neutral, neither overbought nor oversold. The STOCH value of 55.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLS.
SELLAS Life Sciences Group Risk Analysis
SELLAS Life Sciences Group disclosed 77 risk factors in its most recent earnings report. SELLAS Life Sciences Group reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SELLAS Life Sciences Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $1.68B | -48.19 | -47.12% | ― | ― | 41.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $119.76M | -2.61 | -36.37% | ― | -100.00% | -1056.82% | |
48 Neutral | $314.68M | ― | -77.09% | ― | ― | -9.22% | |
46 Neutral | $218.73M | -1.70 | -55.97% | ― | -45.50% | -35.63% | |
41 Neutral | $156.74M | -5.84 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
SLS
SELLAS Life Sciences Group
8.23
6.62
411.18%
GALT
Galectin Therapeutics
2.33
1.01
76.52%
VYGR
Voyager Therapeutics
3.33
-0.21
-5.93%
TLSA
Tiziana Life Sciences
1.24
-0.19
-13.29%
DMAC
Diamedica Therapeutics
5.64
1.50
36.23%
BDTX
Black Diamond Therapeutics
1.97
-0.61
-23.64%
SELLAS Life Sciences Group Corporate Events
Financial DisclosuresPrivate Placements and Financing
SELLAS Life Sciences boosts liquidity through warrant exercises
Positive
Jun 2, 2026
SELLAS Life Sciences Group, Inc. reported that as of March 31, 2026, it held $107.1 million in cash and cash equivalents, providing a snapshot of its financial resources at the end of the first quarter of 2026. The company subsequently strengthene...
Business Operations and StrategyPrivate Placements and Financing
SELLAS Strengthens Capital Base Through Warrant Exercises
Positive
Mar 12, 2026
SELLAS Life Sciences Group, Inc., a biopharmaceutical developer of cancer therapies, continues to build its capital base through the exercise of outstanding common stock warrants. The company focuses on novel oncology treatments for hematologic ca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.